Omega Diagnostics Share Discussion Threads

[rivaldo] 12/1/2018 13:53

Cheers barry - but I can't see any holdings RNS from ODX re Sneller in September? The last one I can see per Investegate is from 21st April, when he had the 14.19m. Cheers.

[barrywhit] 12/1/2018 13:20

Good to see he is still buying and not the seller, which was probably Harwood Capital....IMO

[hyperboreus] 12/1/2018 13:16

Anyhow what is most important is that he thinks ODX is still worthwhile investing in, on the other hand someone else doesn't! 🤓

[barrywhit] 12/1/2018 12:49

Hi Rivaldo,

No he had - Richard Sneller 16,409,157 12.92% as of September 2017 above...

[rivaldo] 12/1/2018 12:44

Indeed - he's now got 17.79m shares - his last holding was only 14.19m, so he's added around 3.6m shares.....

[barrywhit] 12/1/2018 12:40

Richard Sneller still adding to his holding......he has added another 1.3 million

[barrywhit] 11/1/2018 12:49

Looks like the 16p overhang has gone, now paying almost 17p....

[barrywhit] 02/1/2018 10:47

Happy New Year Lads..........

I see we still have sellers.........

[cheshire man] 22/12/2017 09:42

Took a few yesterday happy buying the dip and as rivaldo say's there may be another positive announcement early next year time will tell :-)

[barrywhit] 21/12/2017 07:51

I think that is the first time they have issued a specific RNS when they have received CE Mark for Allergens....normally they just put it in the updates, well done Colin King...

[rivaldo] 21/12/2017 07:43

Quite apart from the good news re the allergens, it's notable that ODX go so far out on a limb to emphasise:

"we remain positive that we will conclude commercialisation discussions with Immunodiagnostic Systems in the near future."

I'd guess there'll be an announcement in the New Year (Jan/Feb) if all goes smoothly.

[verger] 21/12/2017 07:29

A good and positive RNS. All power to Colin King.

[longshanks] 18/12/2017 09:26

Fair plays to you Dibs: I wish you good fortune.No doubt "the cobra" will be back here in due course.

[dibs61] 17/12/2017 23:03

Just for clarification I wasn’t ‘scared’ into selling out (as a PI). It was opportunistic. I spotted what I regard as a better short/medium term opportunity elsewhere. I remain a long term believer in this stock and I am sure I’ll be back but sometimes you have to be ruthless in the AIM market and in the short term I don’t think this is going anywhere. It’ll probably recover to around 16-18p but I doubt anymore until they can show they’ve recovered from the short term headwinds. Meanwhile, hopefully there’s money to be made elsewhere.

ATB to all investors here. Hopefully your patience will be rewarded.

[barrywhit] 16/12/2017 07:26

Turnover of stock has been quite low considering, but the MM's played a blinder dropping the bid to 16p on opening that scared a few PI's into selling out. Hopefully we will see a slow climb backup to 18 to 20p....

[p1nkfish] 16/12/2017 00:27

I can understand some people selling. The turnover in stock hasn't been huge though.

[barrywhit] 15/12/2017 16:23

Dibs was the seller today just posted on the LSE thread, wished him good luck...

[rivaldo] 15/12/2017 16:01

The confidence in the article of the CEO in CD4 in being "not a case of if but when" is welcome:

"Mr Shepherd’s departure from the board comes weeks after the long-awaited commercialisation of Visitect CD4, a product which allows field clinicians to measure the extent of the HIV virus in a carrier’s system and adjust medication accordingly.

The solution could be worth £10m a year for the company.

“It is a significant opportunity in front of us,” said Mr King. “A lot of questions in the past were whether we could bring this product to market. What we’ve proved is that yes we can, and we have, and really now it’s not a case of if but when we start seeing those significant revenues. There is a clear need for the product in the marketplace.”

While the commercialisation of CD4 is a key milestone for the group, Mr King added: “There are other parts of our business we need to grow, not just in global health, but in food and allergy to drive the business and delivery shareholder value. That’s what I’ll be focused on as CEO.”

[barrywhit] 15/12/2017 15:24

Directors haven't bought in the open market for years, and something has changed, confidence in management, and we still have a seller even at 15.5p......

[longshanks] 15/12/2017 15:18

Easy to lose some confidence but nothing much has changed. I would expect David Evans and other directors to buy shares if it stays this low.

[barrywhit] 15/12/2017 14:59

How can the company have got this so wrong, CE marked on its flagship product and you can now buy below 16p........Colin King will have to work miracles..

[gwr7] 15/12/2017 12:45

"Mr Shepherd in 2006 led the company through its successful flotation and has been instrumental in growing the group since its first acquisition of Genesis Diagnostics and Cambridge Nutritional Sciences in August 2007."

It's a kind report for Mr. Shepherd but as for growing the group since those acquisitions in August 2017 the share price is half what it was back then though I appreciate that doesn't take into account shares issued. It was time for somebody else to have a go. I'm glad he's still involved as he seems very committed to CD4 and I'm sure he can promote it with enthusiasm.

[barrywhit] 15/12/2017 11:36

Scottish Herald Link below:

[p1nkfish] 14/12/2017 17:16

In context. About 0.71% of shares changed hands today. Not the end of the world, Just unfortunately to the sales sides.

How will the price respond if there is 0.71 % to the buy side in the next few months.

May well just be sum zero and cagr is the primary victim. Time.

[p1nkfish] 14/12/2017 16:50

I think the changes are necessary.
Operations CEO is positive move, no good as evangelist.

Start-up CEO evangelist spreading the world globally, spot on. Hard to do that and run the show - virtually impossible.

Great inconvenience but that is all it is. Results were already determined before CEO change.

Onwards for LTHS and others can go their merry way.

A big shame about the share price cagr for me but not an existential threat and still believe in the prospects and need for the products/capabilities.